Related Experiment Video
Updated: Jul 17, 2026
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Epstein-Barr virus T-cell immunity despite rituximab
Angela K Nehring1, Ujjwal Dua, Peter Mollee
1EBV Biology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia.
British Journal of Haematology
|January 17, 2007
Summary
Rituximab, used for Epstein-Barr virus (EBV)-positive PTLD, does not impact EBV-specific T-cell immunity. This study found that B cells are not essential for maintaining EBV-specific T-cell responses.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Solid organ transplantation requires immunosuppression, increasing risks of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disorders (PTLD).
- Rituximab, a B-cell targeting antibody, shows efficacy in treating PTLD.
- B cells are considered the primary reservoir for EBV, raising questions about rituximab's impact on EBV-specific T-cell immunity.
Purpose of the Study:
- To investigate the effect of rituximab on the persistence of EBV-specific CD8(+) T-cell immunity.
- To analyze T-cell immunity in a non-transplant setting to isolate rituximab's effects from general immunosuppression.
Main Methods:
- Studied non-transplanted lymphoma patients to avoid confounding immunosuppression from transplantation.
- Assessed EBV-specific CD8(+) T-cell immunity.
- Evaluated cytomegalovirus (CMV)-specific T-cell immunity as an internal control.
Main Results:
- Circulating B cells were found not to be critical for maintaining EBV-specific T-cell immunity.
- Rituximab's impact on EBV-specific T-cell immunity was assessed in a non-PTLD context.
Conclusions:
- The study suggests that B cells may not be essential for the maintenance of EBV-specific T-cell immunity.
- Findings contribute to understanding the immunological consequences of B-cell depletion therapies like rituximab in the context of viral infections.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...